CNSP icon

CNS Pharmaceuticals

1.25 USD
-0.04
3.10%
At close Apr 2, 4:00 PM EDT
After hours
1.31
+0.06
4.80%
1 day
-3.10%
5 days
-10.07%
1 month
-43.18%
3 months
-78.63%
6 months
-79.67%
Year to date
-78.63%
1 year
-99.84%
5 years
-100.00%
10 years
-100.00%
 

About: CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

Employees: 3

0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

8,100% more capital invested

Capital invested by funds: $75.3K [Q3] → $6.17M (+$6.1M) [Q4]

267% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 3

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

62% more funds holding

Funds holding: 13 [Q3] → 21 (+8) [Q4]

2.88% more ownership

Funds ownership: 1.79% [Q3] → 4.68% (+2.88%) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for CNSP.

Financial journalist opinion

Based on 3 articles about CNSP published over the past 30 days

Neutral
Accesswire
1 day ago
CNS Pharmaceuticals Reports Full Year 2024 Financial Results
Company has one year of cash to fund operations Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical efficacy data in glioblastoma multiforme (GBM) for treatment of brain malignancies HOUSTON, TX / ACCESS Newswire / April 1, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the full year ended December 31, 2024 and outlined recent corporate and clinical development highlights. "Oncology drug development can be complex and challenging, but the GBM patients who live with this devastating condition in the shadow of a significant unmet medical need keep us motivated and determined to succeed.
CNS Pharmaceuticals Reports Full Year 2024 Financial Results
Negative
Benzinga
1 week ago
CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects
CNS Pharmaceuticals, Inc.  CNSP on Tuesday announced the primary analysis of its clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM), an aggressive form of brain cancer.
CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects
Neutral
Accesswire
1 week ago
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint. The safety profile continues to be favorable, including the absence of anthracycline related cardiotoxicity.
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
Neutral
Accesswire
1 month ago
CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing
Cash on hand provides over one year of runway to fund expected operations HOUSTON, TX / ACCESS Newswire / February 26, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today provided an update on its current cash position and discussed the completion of its recent initiative to maintain its listing on the NASDAQ Capital Market ("NASDAQ"). "As we kick off 2025, the Company has never been fundamentally stronger.
CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing
Neutral
Accesswire
1 month ago
CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum
Webcast presentation Wednesday, February 26th at 3:20 PM CET HOUSTON, TX / ACCESS Newswire / February 20, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the 18th Annual European Life Sciences CEO Forum on Wednesday, February 26, 2025 at 3:20 PM CET / 9:20 AM EST in Zurich, Switzerland. In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum
Neutral
Accesswire
1 month ago
CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available here HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it participated in the Virtual Investor "Top 5 for ‘25" On-Demand Conference. As part of the event, John Climaco, Chief Executive Officer of CNS Pharmaceuticals, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the Company in 2025.
CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Neutral
Accesswire
1 month ago
CNS Pharmaceuticals Announces Reverse Stock Split
HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-50 reverse split of its common stock. Beginning on February 21, 2025, the Company's common stock will continue to trade on The Nasdaq Capital Market ("Nasdaq") on a split adjusted basis under the trading symbol "CNSP", but will trade under the following new CUSIP number: 18978H409.
CNS Pharmaceuticals Announces Reverse Stock Split
Neutral
Accesswire
1 month ago
CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit
HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will present at the 6th Glioblastoma Drug Development Summit being held February 18-20, 2025 in Boston, MA. As part of the event, Sandra Silberman, MD, PhD, Chief Medical Officer of CNS will give an oral presentation titled, "The Use of Traditional Chemotherapy with Activity In the Treatment of Glioblastoma: Novel Formulations of an Anthracylcine & a Taxane That Appear to Cross the Blood-Brain Barrier," on Thursday, February 20, 2025 at 10:45 AM ET.
CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit
Neutral
Accesswire
1 month ago
CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference
In-person presentation today, February 10th at 1:15 PM ET   HOUSTON, TX / ACCESS Newswire / February 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the BIO CEO & Investor Conference being held February 10-11, 2025 in New York, NY. Details of the presentation are as follows: Date: Monday, February 10, 2025 Presentation Time: 1:15 PM ET Location: Royale Room In addition to the presentation, management will be available to conduct one-on-one meetings and conference attendees that would like to schedule a meeting with the Company are encouraged to register through the BIO CEO attendee portal.
CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference
Neutral
Accesswire
3 months ago
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024
Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure Register for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET. For the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President of Clinical Operations at CNS Pharmaceuticals will be joined by Key Opinion Leaders: Michael Weller, Prof.
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024
Charts implemented using Lightweight Charts™